Reference

1.      Old LJ. Immunotherapy for cancer. Sci Am. 1996; 275:136-143.

2.      Berkow R, Beers MH. Cancer and the immune system. In: The Merck Manual of Medical Information. Whitehouse Station, NJ; Merck Research Laboratories. 1997: 792-794.

3.      Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 1990;29:545-550.

4.      Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16.

5.      Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and donwregulated by tumor necrosis factor alpha. J Exp Med 1994; 179; 1109-1118

6.      Kiessling R, Wasserman K, Horiguchi S, et al. Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999;48:353-362.

7.      Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.

8.      Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117(5): 1195-1203

9.      Jefford DrM, Maraskovsky E. The use of dendritic cells in cancer therapy. Lancet Oncol 2001; 2(6): 343-353.

10.  de Vries IJ, Eggert AA, Scharenborg NM, Vissers JL, Lesterhuis WJ, Boerman OC, Punt CJ, Adema GJ, Figdor CG. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002; 25(5): 429-38.

11.  Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009; 31(5): 787-98.

12.  Spisek R, Bretaudeau L, Barbieux I, maflah K, Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother 2001; 50: 417-427

13.  Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev. 2000;26:269-286.

< nazad <